Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glycyl-L-a-Aminopimelyl-E-(D-2-Aminoethyl)Phosphonate is an experimental small molecule and peptide-based compound with the chemical formula C11H21N3O7P. It acts as a highly specific, slow, and irreversible inhibitor of D-alanyl-D-alanine carboxypeptidase/transpeptidases (DD-peptidases), which are beta-lactam-sensitive enzymes responsible for the final peptidoglycan cross-linking step in bacterial cell wall biosynthesis. By inhibiting this enzyme, it serves as a transition state analogue for the tetrahedral intermediate in the deacylation step of the carboxypeptidase reaction. This mechanism suggests potential utility in modulating glutamate levels and improving cognitive function, though its primary research focus has been on bacterial enzyme inhibition[4][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Glycyl-L-a-Aminopimelyl-E-(D-2-Aminoethyl)Phosphonate.